Aardvark Therapeutics, Inc. Common Stock (AARD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
4370 La Jolla Village Drive
San Diego, CA 92122
United States of America (the)
Phone
858 225 7696
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
February 13, 2025
| Name | Title | Pay | Year Born |
| Tien-Li Lee | Chief Executive Officer, Secretary & Director | 973,658 | 1975 |
| Nelson Sun | CFO & COO | 603,300 | 1977 |
| Manasi Sinha Jaiman | Chief Medical Officer | 693,039 | 1981 |
| Zhenhuan Zheng | Chief Research Officer | 0 | N/A |
| Danny Villeneuve | Chief Commercial Officer | 0 | N/A |
| Ron Lewis | Vice President & Head of CMC | 0 | N/A |
| Timothy J. Kieffer | Chief Scientific Officer | 0 | 1967 |
| Justin T. Stege | VP and Head of Project Management & Strategy | 0 | N/A |
| Derrick C. Li | Chief Business Officer | 0 | N/A |
| Dvorit Samid | Executive Vice President of Medical Affairs | 0 | N/A |
| Terrie Kellmeyer | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Christian Zapf | General Counsel | 0 | N/A |
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.